ATP2B1

Across TCGA pan-cancer cohorts, ATP2B1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ATP2B1 data layer compared with 28 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ATP2B1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ATP2B1 expression acts as an unfavorable survival marker, although some lineages such as LSCC and GBM show a favorable association.

CCRCC, HNSC, and LSCC are the cancer types where ATP2B1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	II,III,IV	0.409	0.793	<.001	44	view →
HNSC	DFS	Tertile	All	0.284	0.832	.008	38	view →
LSCC	OS	Quartile	II,III,IV	1.000	0.644	.014	25	view →
GBM	OS	Median	All	0.956	0.758	.029	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ATP2B1–CCRCC (DFS)

Open the CCRCC breakdown →